Cargando…
Developing high-affinity decoy receptors to treat multiple myeloma and diffuse large B cell lymphoma
Disease relapse and treatment-induced immunotoxicity pose significant clinical challenges for patients with hematological cancers. Here, we reveal distinctive requirements for neutralizing TNF receptor ligands APRIL and BAFF and their receptor activity in MM and DLBCL, impacting protein translation...
Autores principales: | Miao, Yu Rebecca, Thakkar, Kaushik, Cenik, Can, Jiang, Dadi, Mizuno, Kazue, Jia, Chenjun, Li, Caiyun Grace, Zhao, Hongjuan, Diep, Anh, Xu, Yu, Zhang, Xin Eric, Yang, Teddy Tat Chi, Liedtke, Michaela, Abidi, Parveen, Leung, Wing-sze, Koong, Albert C., Giaccia, Amato J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Rockefeller University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428257/ https://www.ncbi.nlm.nih.gov/pubmed/35881112 http://dx.doi.org/10.1084/jem.20220214 |
Ejemplares similares
-
Identification of Doxorubicin as an Inhibitor of the IRE1α-XBP1 Axis of the Unfolded Protein Response
por: Jiang, Dadi, et al.
Publicado: (2016) -
Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in Ovarian Cancer
por: Miao, Yu Rebecca, et al.
Publicado: (2021) -
CSAR Data Set Release 2012: Ligands, Affinities, Complexes,
and Docking Decoys
por: Dunbar, James B., et al.
Publicado: (2013) -
The HIF target MAFF promotes tumor invasion and metastasis through IL11 and STAT3 signaling
por: Moon, Eui Jung, et al.
Publicado: (2021) -
Creation of RANKL mutants with low affinity for decoy receptor OPG and their potential anti‐fibrosis activity
por: Wang, Yizhou, et al.
Publicado: (2019)